Section
Interim data from the multicentre REVEAL study demonstrate that anifrolumab facilitates rapid disease control in real-world SLE patients, with 66% achieving low disease activity within six months, particularly in those with mucocutaneous an
The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.
A comprehensive meta-analysis of double-blind RCTs by the CTT Collaboration reveals that the majority of adverse effects listed on statin labels, including cognitive and sleep issues, lack causal evidence, suggesting a need for urgent regul
A large-scale matched cohort study from the UK Biobank identifies in-hospital delirium as a sentinel marker for long-term multisystem vulnerability. Associated with increased risks of sepsis, AKI, and falls, delirium signals a profound phys
A large multicenter cohort study demonstrates that the number of geriatric syndromes at hospital admission is independently and incrementally associated with 90-day mortality, suggesting that cumulative geriatric burden is a critical progno
This study reveals that young adults with childhood-onset complex chronic conditions (4Cs) account for over 10% of hospital bed-days despite being a small patient volume. They face longer stays, higher costs, and frequent readmissions, high
The DECAF randomized trial challenges the traditional view of caffeine as a trigger for atrial fibrillation, demonstrating that coffee consumption significantly reduces arrhythmia recurrence after cardioversion compared to total abstinence.
This article explores the multi-faceted health benefits of tart cherry juice, from its potent anti-inflammatory properties to its role in enhancing sleep and cardiovascular health, supported by the latest clinical research.
A breakthrough study in Science reveals that the antifibrotic drug finerenone restores fertility in premature ovarian insufficiency (POI) by reducing ovarian stromal fibrosis, enabling follicle development where hormone therapy previously f
A comprehensive systematic review and meta-analysis of 43 studies reveals that Equity, Diversity, and Inclusion (EDI) programs significantly increase minority representation and improve institutional culture, with a 73% increase in the odds
A Phase 1 study of CT-388, a novel signaling-biased dual GLP-1/GIP receptor agonist, demonstrated up to 8% body weight reduction in 28 days with a safety profile consistent with existing incretin therapies, signaling a potential shift in me
The OmniHeart trial reveals that replacing dietary carbohydrates with unsaturated fats or protein favorably modifies 15 minor protein-based HDL subspecies, shifting the proteomic profile toward lower coronary heart disease risk, independent
This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic
A Phase 1b trial demonstrates that the once-weekly insulin GZR4 is safe, well-tolerated, and effective in lowering FPG and HbA1c in patients with T2DM, potentially offering a more convenient alternative to daily basal insulin.
A new study reveals that combining Empagliflozin with Linagliptin reverses urinary dysbiosis in T2D patients, potentially reducing the risk of urogenital infections and improving treatment adherence compared to SGLT2 inhibitor monotherapy.
A post-hoc analysis demonstrates that baseline insulin secretion identifies responders to abatacept in Stage 1 T1D. High-secretors experienced a 15.8-month delay in disease progression and a 54% reduction in risk, providing the first eviden
A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul
This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potenti
Recent studies from the UK Biobank and Framingham Heart Study reveal that evening chronotypes face higher cardiovascular risks, largely mediated by poor adherence to the Life’s Essential 8 (LE8) health metrics, highlighting the critical rol
A cross-sectional analysis of the HOPE Consortium Trial reveals that chronic pain in hemodialysis patients is widespread, frequently musculoskeletal and neuropathic, and strongly associated with psychological and sociodemographic factors ra
